In preclinical oncology research, precision and clarity in imaging are essential for understanding tumor biology and evaluating therapeutic efficacy. TD2's advanced imaging services incorporate cutting-edge technologies, with Aura Imaging Software 4.0 being a key component. This software is transforming how researchers capture, analyze, and interpret imaging data, offering unparalleled insights into tumor growth and treatment responses.
1. Smart Exposure for Optimal Image Capture
Aura Imaging Software 4.0 features Smart Exposure, ensuring both faint and strong signals are captured in a single image. This feature streamlines the imaging process, reducing the need for multiple exposures and enhancing data accuracy by preventing overexposure and underexposure.
2. High-Quality Luminescence and Fluorescence Imaging
3. Advanced Data Analysis Tools
The software includes a suite of advanced data analysis tools that provide comprehensive insights into therapeutic effects. Researchers can visualize drug progression in longitudinal studies, monitor treatment efficacy over time, and generate detailed reports to support informed decision-making.
4. Versatile Emission and Excitation Filters
Aura Imaging Software 4.0 supports a variety of emission and excitation filters, offering flexibility in experimental design. This versatility enables researchers to tailor imaging parameters to the specific requirements of their studies, ensuring optimal results.
5. Seamless Integration with Spectral Instruments Imaging AMI HTX
Aura Imaging Software 4.0 is fully integrated with the Spectral Instruments Imaging AMI HTX, a high-efficiency imaging system used by TD2. This seamless integration enhances the overall imaging process, providing researchers with a robust and reliable platform for their studies.
The capabilities of Aura Imaging Software 4.0 are advancing the field of preclinical oncology research. By providing high-resolution, detailed images and advanced data analysis tools, this software enables researchers to gain deeper insights into tumor biology and treatment responses. The precision and clarity offered by Aura 4.0 ensures that preclinical studies are grounded in robust and reliable data, ultimately facilitating the transition to clinical trials.
To learn more about how TD2's imaging capabilities can enhance your preclinical oncology research, visit our webpage on Optical Imaging Services for Preclinical Evaluation. Discover how our advanced technologies and expert services can support your research objectives and drive the development of novel therapies.